Gaps in Use of Antipsychotics After Discharge by First-Admission Patients With Schizophrenia, 1989 to 1996
The authors examined gaps in the use of antipsychotic medications during the one-year period after discharge in an epidemiological sample of 189 first-admission patients with schizophrenia between July 1989 and January 1996. Sixty-three percent of the patients had one or more such gaps, and 51 perce...
Gespeichert in:
| Veröffentlicht in: | Psychiatric services (Washington, D.C.) D.C.), 2002-03, Vol.53 (3), p.337-339 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 339 |
|---|---|
| container_issue | 3 |
| container_start_page | 337 |
| container_title | Psychiatric services (Washington, D.C.) |
| container_volume | 53 |
| creator | Mojtabai, Ramin Lavelle, Janet Gibson, P. Joseph Sohler, Nancy L. Craig, Thomas J. Carlson, Gabrielle A. Bromet, Evelyn J. |
| description | The authors examined gaps in the use of antipsychotic medications during the one-year period after discharge in an epidemiological sample of 189 first-admission patients with schizophrenia between July 1989 and January 1996. Sixty-three percent of the patients had one or more such gaps, and 51 percent had gaps of 30 days or longer, with an average total time off medication of about seven months. Most gaps occurred soon after discharge, and 73 percent were initiated by the patient. These data, which were obtained before the widespread use of atypical antipsychotic agents, provide a benchmark against which to examine the impact of the newer medications on adherence and continuity of treatment in the critical early stages of schizophrenia. |
| doi_str_mv | 10.1176/appi.ps.53.3.337 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71497563</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71497563</sourcerecordid><originalsourceid>FETCH-LOGICAL-a363t-9792a816f93460cadfda5d04031b7a543c550c009734cdc36b4342fe23845723</originalsourceid><addsrcrecordid>eNp1kTFvFDEQhS0EIiHQUyE3ULHHeGe9XpenQAJSJJAIorR8Xi_r093aeHzF8etxuJNSoSlmiu-9Gb1h7LWAlRCq_2BTCqtEK4mrWqiesEshpWq0AnhaZ1CyaRXCBXtBtAUAoUT_nF0IMSjZIlyy7a1NxMPCf5DnceLrpYRERzfHEhzx9VR85h8DudnmX55vjvwmZCrNetwHohAX_s2W4JdC_GcoM__u5vAnpjn7Jdj3XOhB8xJr1_1L9myyO_Kvzv2K3d98ur_-3Nx9vf1yvb5rLPZY6u26tYPoJ41dD86O02jlCB2g2CgrO3RSggPQCjs3Ouw3HXbt5FscOqlavGLvTrYpx98HT8XUS53f7ezi44GMEp1WsscKwgl0ORJlP5mUw97moxFgHuI1D_GaREaiqYWqSt6cvQ-bvR8fBec8K_D2DFhydjdlu7hAjxzW74AeKtecuH8rtvGQlxrJ_xf_BSV9kZs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71497563</pqid></control><display><type>article</type><title>Gaps in Use of Antipsychotics After Discharge by First-Admission Patients With Schizophrenia, 1989 to 1996</title><source>MEDLINE</source><source>Psychiatry Legacy Collection Online Journals 1844-1996</source><source>American Psychiatric Publishing Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Mojtabai, Ramin ; Lavelle, Janet ; Gibson, P. Joseph ; Sohler, Nancy L. ; Craig, Thomas J. ; Carlson, Gabrielle A. ; Bromet, Evelyn J.</creator><creatorcontrib>Mojtabai, Ramin ; Lavelle, Janet ; Gibson, P. Joseph ; Sohler, Nancy L. ; Craig, Thomas J. ; Carlson, Gabrielle A. ; Bromet, Evelyn J.</creatorcontrib><description>The authors examined gaps in the use of antipsychotic medications during the one-year period after discharge in an epidemiological sample of 189 first-admission patients with schizophrenia between July 1989 and January 1996. Sixty-three percent of the patients had one or more such gaps, and 51 percent had gaps of 30 days or longer, with an average total time off medication of about seven months. Most gaps occurred soon after discharge, and 73 percent were initiated by the patient. These data, which were obtained before the widespread use of atypical antipsychotic agents, provide a benchmark against which to examine the impact of the newer medications on adherence and continuity of treatment in the critical early stages of schizophrenia.</description><identifier>ISSN: 1075-2730</identifier><identifier>EISSN: 1557-9700</identifier><identifier>DOI: 10.1176/appi.ps.53.3.337</identifier><identifier>PMID: 11875230</identifier><language>eng</language><publisher>Washington, DC: American Psychiatric Publishing</publisher><subject>Adult ; Adult and adolescent clinical studies ; Antipsychotic Agents - therapeutic use ; Benchmarking ; Biological and medical sciences ; Continuity of Patient Care ; Female ; Humans ; Male ; Medical sciences ; Mental Health Services - utilization ; Neuropharmacology ; Patient Admission - statistics & numerical data ; Patient Compliance ; Pharmacology. Drug treatments ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychoses ; Retrospective Studies ; Schizophrenia ; Schizophrenia - drug therapy ; Schizophrenia - rehabilitation</subject><ispartof>Psychiatric services (Washington, D.C.), 2002-03, Vol.53 (3), p.337-339</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a363t-9792a816f93460cadfda5d04031b7a543c550c009734cdc36b4342fe23845723</citedby><cites>FETCH-LOGICAL-a363t-9792a816f93460cadfda5d04031b7a543c550c009734cdc36b4342fe23845723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/appi.ps.53.3.337$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/appi.ps.53.3.337$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,780,784,2855,2859,21626,21627,21628,21629,27924,27925,77791,77792,77794,77799</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13557098$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11875230$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mojtabai, Ramin</creatorcontrib><creatorcontrib>Lavelle, Janet</creatorcontrib><creatorcontrib>Gibson, P. Joseph</creatorcontrib><creatorcontrib>Sohler, Nancy L.</creatorcontrib><creatorcontrib>Craig, Thomas J.</creatorcontrib><creatorcontrib>Carlson, Gabrielle A.</creatorcontrib><creatorcontrib>Bromet, Evelyn J.</creatorcontrib><title>Gaps in Use of Antipsychotics After Discharge by First-Admission Patients With Schizophrenia, 1989 to 1996</title><title>Psychiatric services (Washington, D.C.)</title><addtitle>Psychiatr Serv</addtitle><description>The authors examined gaps in the use of antipsychotic medications during the one-year period after discharge in an epidemiological sample of 189 first-admission patients with schizophrenia between July 1989 and January 1996. Sixty-three percent of the patients had one or more such gaps, and 51 percent had gaps of 30 days or longer, with an average total time off medication of about seven months. Most gaps occurred soon after discharge, and 73 percent were initiated by the patient. These data, which were obtained before the widespread use of atypical antipsychotic agents, provide a benchmark against which to examine the impact of the newer medications on adherence and continuity of treatment in the critical early stages of schizophrenia.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Benchmarking</subject><subject>Biological and medical sciences</subject><subject>Continuity of Patient Care</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental Health Services - utilization</subject><subject>Neuropharmacology</subject><subject>Patient Admission - statistics & numerical data</subject><subject>Patient Compliance</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychoses</subject><subject>Retrospective Studies</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - rehabilitation</subject><issn>1075-2730</issn><issn>1557-9700</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kTFvFDEQhS0EIiHQUyE3ULHHeGe9XpenQAJSJJAIorR8Xi_r093aeHzF8etxuJNSoSlmiu-9Gb1h7LWAlRCq_2BTCqtEK4mrWqiesEshpWq0AnhaZ1CyaRXCBXtBtAUAoUT_nF0IMSjZIlyy7a1NxMPCf5DnceLrpYRERzfHEhzx9VR85h8DudnmX55vjvwmZCrNetwHohAX_s2W4JdC_GcoM__u5vAnpjn7Jdj3XOhB8xJr1_1L9myyO_Kvzv2K3d98ur_-3Nx9vf1yvb5rLPZY6u26tYPoJ41dD86O02jlCB2g2CgrO3RSggPQCjs3Ouw3HXbt5FscOqlavGLvTrYpx98HT8XUS53f7ezi44GMEp1WsscKwgl0ORJlP5mUw97moxFgHuI1D_GaREaiqYWqSt6cvQ-bvR8fBec8K_D2DFhydjdlu7hAjxzW74AeKtecuH8rtvGQlxrJ_xf_BSV9kZs</recordid><startdate>20020301</startdate><enddate>20020301</enddate><creator>Mojtabai, Ramin</creator><creator>Lavelle, Janet</creator><creator>Gibson, P. Joseph</creator><creator>Sohler, Nancy L.</creator><creator>Craig, Thomas J.</creator><creator>Carlson, Gabrielle A.</creator><creator>Bromet, Evelyn J.</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020301</creationdate><title>Gaps in Use of Antipsychotics After Discharge by First-Admission Patients With Schizophrenia, 1989 to 1996</title><author>Mojtabai, Ramin ; Lavelle, Janet ; Gibson, P. Joseph ; Sohler, Nancy L. ; Craig, Thomas J. ; Carlson, Gabrielle A. ; Bromet, Evelyn J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a363t-9792a816f93460cadfda5d04031b7a543c550c009734cdc36b4342fe23845723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Benchmarking</topic><topic>Biological and medical sciences</topic><topic>Continuity of Patient Care</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental Health Services - utilization</topic><topic>Neuropharmacology</topic><topic>Patient Admission - statistics & numerical data</topic><topic>Patient Compliance</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychoses</topic><topic>Retrospective Studies</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - rehabilitation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mojtabai, Ramin</creatorcontrib><creatorcontrib>Lavelle, Janet</creatorcontrib><creatorcontrib>Gibson, P. Joseph</creatorcontrib><creatorcontrib>Sohler, Nancy L.</creatorcontrib><creatorcontrib>Craig, Thomas J.</creatorcontrib><creatorcontrib>Carlson, Gabrielle A.</creatorcontrib><creatorcontrib>Bromet, Evelyn J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Psychiatric services (Washington, D.C.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mojtabai, Ramin</au><au>Lavelle, Janet</au><au>Gibson, P. Joseph</au><au>Sohler, Nancy L.</au><au>Craig, Thomas J.</au><au>Carlson, Gabrielle A.</au><au>Bromet, Evelyn J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gaps in Use of Antipsychotics After Discharge by First-Admission Patients With Schizophrenia, 1989 to 1996</atitle><jtitle>Psychiatric services (Washington, D.C.)</jtitle><addtitle>Psychiatr Serv</addtitle><date>2002-03-01</date><risdate>2002</risdate><volume>53</volume><issue>3</issue><spage>337</spage><epage>339</epage><pages>337-339</pages><issn>1075-2730</issn><eissn>1557-9700</eissn><abstract>The authors examined gaps in the use of antipsychotic medications during the one-year period after discharge in an epidemiological sample of 189 first-admission patients with schizophrenia between July 1989 and January 1996. Sixty-three percent of the patients had one or more such gaps, and 51 percent had gaps of 30 days or longer, with an average total time off medication of about seven months. Most gaps occurred soon after discharge, and 73 percent were initiated by the patient. These data, which were obtained before the widespread use of atypical antipsychotic agents, provide a benchmark against which to examine the impact of the newer medications on adherence and continuity of treatment in the critical early stages of schizophrenia.</abstract><cop>Washington, DC</cop><pub>American Psychiatric Publishing</pub><pmid>11875230</pmid><doi>10.1176/appi.ps.53.3.337</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1075-2730 |
| ispartof | Psychiatric services (Washington, D.C.), 2002-03, Vol.53 (3), p.337-339 |
| issn | 1075-2730 1557-9700 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71497563 |
| source | MEDLINE; Psychiatry Legacy Collection Online Journals 1844-1996; American Psychiatric Publishing Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Adult and adolescent clinical studies Antipsychotic Agents - therapeutic use Benchmarking Biological and medical sciences Continuity of Patient Care Female Humans Male Medical sciences Mental Health Services - utilization Neuropharmacology Patient Admission - statistics & numerical data Patient Compliance Pharmacology. Drug treatments Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Psychoses Retrospective Studies Schizophrenia Schizophrenia - drug therapy Schizophrenia - rehabilitation |
| title | Gaps in Use of Antipsychotics After Discharge by First-Admission Patients With Schizophrenia, 1989 to 1996 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T02%3A19%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gaps%20in%20Use%20of%20Antipsychotics%20After%20Discharge%20by%20First-Admission%20Patients%20With%20Schizophrenia,%201989%20to%201996&rft.jtitle=Psychiatric%20services%20(Washington,%20D.C.)&rft.au=Mojtabai,%20Ramin&rft.date=2002-03-01&rft.volume=53&rft.issue=3&rft.spage=337&rft.epage=339&rft.pages=337-339&rft.issn=1075-2730&rft.eissn=1557-9700&rft_id=info:doi/10.1176/appi.ps.53.3.337&rft_dat=%3Cproquest_cross%3E71497563%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71497563&rft_id=info:pmid/11875230&rfr_iscdi=true |